Summit Therapeutics plc Summit Therapeutics Plc : Grant Of Share Options
June 28 2017 - 1:00AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit" or the "Company")
GRANT OF SHARE OPTIONS
Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ:
SMMT), the drug discovery and development company advancing therapies
for Duchenne muscular dystrophy and C. difficile infection, announces
that on 27 June 2017 it granted share options over 34,711 new ordinary
shares of 1p nominal value ("Shares") at an exercise price of 180 pence
per Share to employees of the Company. These options will vest in nine
equal tranches on a quarterly basis from 27 June 2018 and will vest in
full on 27 June 2020.
The above exercise price is the mid-market closing price of Summit's
Shares on 26 June 2017. These option awards have been made under the
Company's 2016 Long Term Incentive Plan.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014.
- END -
For more information, please contact:
Summit Therapeutics
Richard Pye (UK office) Tel: +44 (0)1235 443 951
Erik Ostrowski (US office) +1 617 294 6607
Cairn Financial Advisers LLP
(Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
June 28, 2017 02:00 ET (06:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Ther News Articles